Recently, it has been reported that linc-RoR is able to activate the MAPK/ERK signaling pathway through the regulation of the ERK-specific phosphatase DUSP7 in ER+ BC, which bypasses the ER signaling pathway thus facilitating the development of intrinsic resistance to endocrine therapy 25 (Figure 2). The gene discussed is LINC-ROR; the disease is breast cancer.